Ibuzatrelvir
Alternative Names: PF-07817883Latest Information Update: 12 Feb 2024
At a glance
- Originator Pfizer
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus-3C-like-proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II COVID 2019 infections
Most Recent Events
- 12 Jan 2024 Pfizer completes a phase I study in Covid-2019 infections (In volunteers) in Belgium (PO, Tablet) (NCT06122194)
- 29 Nov 2023 Pfizer initiates a phase I trial (In volunteers) (PO, Tablet) (NCT06122194)
- 08 Nov 2023 Pfizer plans a phase I trial (In volunteers) (PO) in November 2023 (NCT06122194)